Compare Lowe`s Companies Inc (LOW) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lowe`s Companies Inc vs Tango Therapeutics Inc. — how do they compare? Lowe`s Companies Inc trades at $191.01 (market cap $105.65B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Lowe`s Companies Inc is far larger — about 28.2× Tango Therapeutics Inc.'s market cap, and Lowe`s Companies Inc pays a 2.66% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lowe`s Companies Inc for 98 Days and Tango Therapeutics Inc. for 0 Days on average.
| LOW | TNGX | |
|---|---|---|
Market Cap | $105.65B | $3.74B |
Volume | 1,711,895 | 3,438,781 |
Sector | Consumer Cyclical | Health |
52-Week High | $287.39 | $32.90 |
52-Week Low | $179.50 | $7.50 |
Typical Hold Time | 98 Days | 0 Days |
Enterprise Value | $144.50B | $2.76B |
Dividend Yield | 2.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lowe's (LOW) trades at $188.77, up 1.72% with recent earnings beats but faces bearish technical signals. The stock shows solid fundamentals with a P/E of 15.95 and net margin of 7.35%, though revenue declined to $83.67B in 2025. Recent news highlights drone delivery innovation with DoorDash and Alphabet, while analyst consensus remains strongly bullish with a $244.09 price target representing 29% upside potential.
LOW presents a value opportunity with attractive valuation metrics and consistent dividend payments, but faces headwinds from slowing home improvement demand and elevated debt levels. The stock's negative shareholder equity and competitive pressure from Home Depot require careful monitoring, though institutional support remains strong with 60.79% buy ratings.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
